POLD1 and neoplasm: In addition to the absence of other known actionable driver mutations, NTRK+ CRC tumors harbor very high tumor mutation burden (median 53 mut/MB), with most of them being microsatellite instability‐high (MSI‐H), and an enrichment of POLE/POLD1 mutations.